Antonio Giordano, MD PhD
@antgiorda
Breast Medical Oncologist @harvardmed @DanaFarber driven by passion for #research and the one for taking care of #breastcancer patients #bcsm 🇮🇹🇺🇸
Look! The @The_Right_Dose survey was featured at #HarvardBreastCancerCourse by @antgiorda—thanks for highlighting dosing in your Phase 1 trials talk! Anne Loeser was the brains and engine behind this work, and the whole team played an integral role: therightdose.org/about-us#team
Dr. Antonio Giordano (@antgiorda) discussed the importance of Phase I trials and early #DrugDiscovery in #BreastCancer. #HarvardBreastCancerCourse
Living in my dream ❤️❤️❤️❤️ Thank you!!! 💜💚 @Wimbledon
Congratulations to Dr. Filipa Lynce (@FilipaLynce) recipient of the Women’s Health Collaboration Award from the @MALifeSciences! This award supports collaborative projects that aim to improve the discovery, technical innovation, and analysis of datasets to answer pressing life…
Such a strong signal for our new partnership with BIDMC. You just got the best breast surgeon to lead the Program!
We’re proud to announce that Elizabeth Mittendorf, MD, will join BIDMC as Chief of a new Division of Breast Surgery! 👏 A renowned surgeon, she will bring bold leadership to our growing program in collaboration with Dana-Farber. Learn more: bidmc.org/about-bidmc/ne…
A nice patient friendly article on how metastases occur in breast cancer and how cells adapt to their metastatic environment. #bcsm knowablemagazine.org/content/articl…
📢 Just out in Cancer Treatment Reviews! We explore a key challenge in HR+/HER2– BC: resistance to CDK4/6i. 💡 Why it happens 🔄 How to overcome it with combos 🚀 What’s next Proud of the great collaborative effort behind this work. 📖 doi.org/10.1016/j.ctrv…
Pratik Joshi had been living in London for six years. A software professional, he’d long dreamed of building a life abroad for his wife and three young children, who stayed back in India. After years of waiting for due clearances the dream was finally coming true. Just two days…
Chemotherapy can save lives, but it can also come with challenges like #PeripheralNeuropathy. Ting Bao, MD, MS, (@tingbao2011) co-director of the @DanaFarberZakim breaks down #ChemotherapyInducedPeripheralNeuropathy. Watch the webinar to learn about the causes, symptoms, risk…
The highly awaited @DrHBurstein ASCO Highlights lecture once more delivers education, great food for thoughts and FUN! @DFCI_BreastOnc
What to look forward the most after @ASCO Annual Meeting. The @DrHBurstein #ASCO25 Highlights. Starting with differences between "formerly a big deal" vs "k of the moment" and its proof @stolaney1 @DFCI_BreastOnc
What to look forward the most after @ASCO Annual Meeting. The @DrHBurstein #ASCO25 Highlights. Starting with differences between "formerly a big deal" vs "k of the moment" and its proof @stolaney1 @DFCI_BreastOnc
Congrats and well deserved @FilipaLynce
Congrats @FilipaLynce!
Dr. Beatrice Wiafe-Addai's visit truly highlights the global challenges in cancer care, particularly in regions like Ghana where resource limitations pose significant hurdles. It raises important questions about how advancements in treatment can be equitably accessed worldwide.…
Such an honor to have Dr. Beatrice Wiafe-Addai visiting @DanaFarber for few days. Interesting prospective of cancer care from 🇬🇭 Ghana where drug armamentarium is so limited. #cancerdisparity #westafrica @DanaFarberNews @DFCI_BreastOnc
🚨 If you're as serious about breast cancer care as @DrReshmaMahtani, @baik_alan, @antgiorda, @DrSGraff, @claudine_isaacs, @FilipaLynce, @hmcarthur, @DrKEMcCann, @folopade, @kristinrojasmd, @drsarahsam, @Dr_RShatsky, @BCJoyceO then you won't miss #PBCCLive25 in DC! It's the…
Check out this recent review on the management of metastatic hormone receptor-positive #BreastCancer Beyond CDK4/6 Inhibitors. 🔓pubmed.ncbi.nlm.nih.gov/40434676/ ✍️@antgiorda @elmayermd @stolaney1 @PTarantinoMD @IlanaSchlam @AnaGarridoCastro
Dream team breast cancer researchers @DFCI_BreastOnc @DanaFarber pioneering advancement therapeutics for patients #bcsm @ASCO @stolaney1 @AnnPartridgeMD @DrHBurstein @nlinmd @elmayermd @drsarahsam @FilipaLynce @adawaksmd @hthrparsons @IlanaSchlam @esalehiDNP @PTarantinoMD
Another highlight of #ASCO2025: reconnecting with my mentors and colleagues. @DFCI_BreastOnc @stolaney1 @drsarahsam @PTarantinoMD @FilipaLynce @antgiorda @elmayermd @StefiMorganti @nlinmd
15 Posts Not to Miss from the 4th Day of ASCO 2025 @antgiorda | @ArmandOrlandi | @ArndtVogel | @Dr_ElvinaA | @g_mountzios | @KimrynRathmell | @PTarantinoMD | @pashtoonkasi | @RobinZo41054013 | @_ShankarSiva | @LoiblSibylle | @weldeiry oncodaily.com/societies/asco… #ASCO #ASCO2025…
🔔Practice change alert for breast cancer physicians #bcsm ‼️Schedule your K522 and ascent-04 pts in the morning‼️ Randomized clinical trial shows improved OS…HR 0.45, for lung ca patients receiving NACT with immunotherapy in the morning #ASCO25 @DrHBurstein
Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive! Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival.…